1. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine 2004;10:S122-S9.
2. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016;529:336-43.
3. Tateda K. Diagnosis treatment and prevention of infectious diseases: Topics: III. Various problems in antimicrobial agents; 1. Strategy and direction to overcome stagnation of antibiotic development. Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine 2013;102:2908-14.
4. Hamad B. The antibiotics market. Nature reviews Drug discovery 2010;9:675.
5. Gao W-Y, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2', 3'-dideoxynucleosides. Molecular Pharmacology 1994;46:767-72.
6. Gao W-Y, Johns DG, Chokekuchai S, et al. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2', 3'-dideoxynucleoside activities against replication of human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America 1995;92:8333.
7. Kerantzas CA, Jacobs WR Jr. Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application. mBio 2017;8:e01586-16.
8. Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Archives of internal medicine 2003;163:402-10.
9. Wrobel A, Arciszewska K, Maliszewski D, et al. Trimethoprim and other nonclassical antifolatesan excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
10. Smith JR, Barber KE, Raut A, et al. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. Journal of Antimicrobial Chemotherapy 2015;70:1738-43.
11. Kaushik A, Makkar N, Pandey P, et al. Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy 2015;59:6561-7.
12. Roger P, Amanda M, Ole K, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Archives of internal medicine 2000;160:1123-32.
13. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metabolism 2017;25:27-42.
14. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nature Reviews Cancer 2013;13:572-83.
15. Shetty S, Varshney U. Regulation of translation by one-carbon metabolism in bacteria and eukaryotic organelles. Journal of Biological Chemistry 2021:100088.
16. Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nature Reviews Cancer 2016;16:650-62.
17. Renwick SB, Snell K, Baumann U. The crystal structure of human cytosolic serine hydroxymethyltransferase: a target for cancer chemotherapy. Structure 1998;6:1105-16.
18. Anderson DD, Woeller CF, Chiang E-P, et al. Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. Journal of Biological Chemistry 2012;287:7051-62.
19. Tibbetts AS, Appling DR. Compartmentalization of Mammalian folate-mediated one- carbon metabolism. Annual Review of Nutrition 2010;30:57-81.
20. Raimondi MV, Randazzo O, La Franca M, et al. DHFR inhibitors: reading the past for discovering novel anticancer agents. Molecules 2019;24:1140.
21. Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature reviews Clinical Oncology 2014;11:282- 98
22. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer 2003;3:330-8.
23. Van Triest B, Pinedo H, Giaccone G, et al. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Annals of Oncology 2000;11:385-91.
24. Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annual Reviews 1998;52:591-625
25. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacology & Therapeutics 1990;48:381-95.
26. Gonen N, Assaraf YG. Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. Drug Resistance Updates 2012;15:183-210
27. Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs–antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2014;29:379-87.
28. Galmarini CM, Mackey JR, Dumontet C, Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncology 2002;3:415-24.
29. Oe C, Hayashi H, Hirata K, et al. Pyrimidine analogues as a new class of Gram-positive antibiotics, mainly targeting thymineless-death related proteins. ACS Infectious Diseases 2019;6:1490-500.
30. Liang J, Han Q, Tan Y, et al. Current advances on structure-function relationships of pyridoxal 5′-phosphate-dependent enzymes. Frontiers in Molecular Biosciences 2019;6:4.
31. Scarsdale JN, Radaev S, Kazanina G, et al. Crystal structure at 2.4 Å resolution of E. coli serine hydroxymethyltransferase in complex with glycine substrate and 5-formyl tetrahydrofolate. Journal of Molecular Biology 2000;296:155-68.
32. Giardina G, Paone A, Tramonti A, et al. The catalytic activity of serine hydroxymethyltransferase is essential for de novo nuclear dTMP synthesis in lung cancer cells. The FEBS journal 2018;285:3238-53.
33. Garrow TA, Brenner A, Whitehead VM, et al. Cloning of human cDNAs encoding mitochondrial and cytosolic serine hydroxymethyltransferases and chromosomal localization. Journal of Biological Chemistry 1993;268:11910-6.
34. Paiardini A, Tramonti A, Schirch D, et al. Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming. Biochimica et Biophysica Acta - Proteins and Proteomics 2016;1864:1506-1517.
35. Ducker GS, Ghergurovich JM, Mainolfi N, et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2017;114:11404-9.
36. Zhang Y, Guo R, Kim SH, et al. SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication. Nature Communications 2021;12:1-11.
37. Witschel MC, Rottmann M, Schwab A, et al. Inhibitors of plasmodial serine hydroxymethyltransferase (SHMT): cocrystal structures of pyrazolopyrans with potent blood- and liver-stage activities. Journal of Medicinal Chemistry 2015;58:3117-30.
38. Schwertz G, Witschel MC, Rottmann M, et al. Antimalarial inhibitors targeting serine hydroxymethyltransferase (SHMT) with in vivo efficacy and analysis of their binding mode based on X-ray cocrystal structures. Journal of Medicinal Chemistry 2017;60:4840-60.
39. García-Cañaveras JC, Lancho O, Ducker GS, et al. SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. Leukemia 2021;35:377- 388
40. Geeraerts SL, et al. Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth. Molecular Cancer Therapeutics 2021;20:50-63.
41. Geeraerts, SL, Heylen E, Keersmaecker D, et al. The ins and outs of serine and glycine metabolism in cancer. Nature Metabolism 2021;3:131-141.
42. Tramonti A, Paiardini A, Paone A, et al. Angela Tramonti. Differential inhibitory effect of a pyrazolopyran compound on human serine hydroxymethyltransferase-amino acid complexes. Archives of Biochemistry and Biophysics 2018;653:71-79.
43. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nature Reviews Microbiology 2012;10:266–278.
44. Raza T, Ullah SR, Mehmood K, et al. Vancomycin resistant Enterococci: A brief review. Journal of Pakistan Medical Association 2018;68:768-772
45. Cetinkaya Y, Falk P, Mayhall CG, et al. Vancomycin-Resistant Enterococci. Clinical Microbiology Reviews 2000;13:686-707
46. Fiore E, Tyne DV, Gilmore MS. Pathogenicity of Enterococci. Microbiology Spectrum 2019;7:1-23
47. 国立感染症研究所, 厚生労働省健康局結核感染症課. 病原体微生物検出情報（Infectious Agents Surveillance Report; IASR）2021:42:155-176
48. 厚生労働省，国立感染症研究所. 感染症発生動向調査 (Infectious Diseases Weeklu Report Japan; IDWR). 2003-2021
49. Rossi M, Amaretti A, Raimondi S. Folate production by probiotic bacteria. Nutrients 2011;3:118-34.
50. Omura S, Murata M, Kimura K, et al. Screening for new antifolates of microbial origin and a new antifolate AM-8402. Journal of Antibiotics 1985;38:1016-24.
51. Tomoda H, Omura S. New strategy for discovery of enzyme inhibitors: screening with intact mammalian cells or intact microorganisms having special functions. Journal of Antibiotics 1990;43:1207-22.
52. Swier LJ, Guskov A, Slotboom DJ. Structural insight in the toppling mechanism of an energy-coupling factor transporter. Nature Communications 2016;7:1-11.
53. Daniel DJ, Hsuueh P, Mendes RE, et al. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy 2019;63:e00355-19.
54. MRSA 感染症の治療ガイドライン. 公益社団法人日本化学療法学会・一般社団法人日本感染症学会. 改訂版 2019
55. Nakagawara K, Hayashi H, Kawaji K, et al. Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. Antiviral Chemistry and Chemotherapy 2020;28:2040206620921319.
56. Izumi K, Watanabe K, Oishi S, et al. Potent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20. Antiviral Chemistry and Chemotherapy 2011;22:51-5.
57. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 2006;58:621-81.
58. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature Protocols 2007;2:2212-21.
59. Hayashi H, Takamune N, Nirasawa T, et al. Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proceedings of the National Academy of Sciences 2014;111:12234-9.
60. Ueno G, Kanda H, Hirose R, et al. RIKEN structural genomics beamlines at the SPring- 8; high throughput protein crystallography with automated beamline operation. Journal of Structural and Functional Genomics 2006;7:15-22.
61. Ito S, Ueno G, Yamamoto M. DeepCentering: fully automated crystal centering using deep learning for macromolecular crystallography. Journal of Synchrotron Radiation 2019;26:1361-6.
62. Okazaki N, Hasegawa K, Ueno G, et al. Mail-in data collection at SPring-8 protein crystallography beamlines. Journal of Synchrotron Radiation 2008;15:288-91.
63. Murakami H, Ueno G, Shimizu N, et al. Upgrade of automated sample exchanger SPACE. Journal of Applied Crystallography 2012;45:234-8.
64. Yamashita K, Hirata K, Yamamoto M. KAMO: towards automated data processing for microcrystals. Acta Crystallographica Section D: Structural Biology 2018;74:441-9.
65. Hirata K, Yamashita K, Ueno G, et al. ZOO: an automatic data-collection system for high-throughput structure analysis in protein microcrystallography. Acta Crystallographica Section D: Structural Biology 2019;75:138-50.
66. Winn MD, Ballard CC, Cowtan KD, et al. Overview of the CCP4 suite and current developments. Acta Crystallographica Section D: Biological Crystallography 2011;67:235-42.
67. Krissinel E. CCP4 Software Suite: history, evolution, content, challenges and future developments. Arbor-Ciencia Pensam Y Cult doi 2015;10.
68. McCoy AJ, Grosse-Kunstleve RW, Adams PD, et al. Phaser crystallographic software. Journal of Applied Crystallography 2007;40:658-74.
69. Hernandez K, Zelen I, Petrillo G, et al. Engineered L‐Serine Hydroxymethyltransferase from Streptococcus thermophilus for the Synthesis of α,α-Dialkyl‐α‐Amino Acids. Angewandte Chemie 2015;127:3056-60.
70. Adams PD, Afonine PV, Bunkóczi G, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D: Biological Crystallography 2010;66:213-21.
71. Zwart PH, Afonine PV, Grosse-Kunstleve RW, et al. Automated structure solution with the PHENIX suite. Structural Proteomics: Springer; 2008:419-35.
72. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallographica section D: Biological Crystallography 2004;60:2126-32.
73. Marani, M., et al. A pyrazolopyran derivative preferentially inhibits the activity of human cytosolic serine hydroxymethyltransferase and induces cell death in lung cancer cells. Oncotarget 2016;7:4570-4583.
74. Anderson DD, Stover PJ. SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis. PloS one 2009;4:e5839.
75. Paone A, Marani M, Fiascarelli A, et al. SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation. Cell Death & Disease 2014;5:e1525-e.
76. Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends in Biochemical Sciences 2014;39:191-8.
77. Greenstein RJ, Su L, Haroutunian V, et al. On the action of methotrexate and 6- mercaptopurine on M. avium subspecies paratuberculosis. PLOS ONE 2007;2:e161.
78. Daidone F, Insilico and in vitro validation of serine hydrooxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed. European Journal of Medicinal Chemistry 2011;46:1616-1621
79. Sato Y, Tomita M, Soga T, et al. Upregulation of Thymidylates Synthase Induces Pemetrexed Resistance in Malignant Pleurai Mesothelioma. Frontiers in phamacology 2021;12:718675
80. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nature Reviews Microbiology 2010;8:423-435
81. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiology and Molecular Biology Reviews 2001;65:232-260
82. Hooper DC. Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones. Clinical Infectious Diseases 2001;32:S9-S15.
83. Ghosh AK, Ramu Sridhar P, Kumaragurubaran N, et al. Bis‐tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem: Chemistry Enabling Drug Discovery 2006;1:939-50.
84. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi- PI-resistant human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy 2003;47:3123-9.
85. Koh Y, Amano M, Towata T, et al. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. Journal of Virology 2010;84:11961-9.
86. Alfadhli S, Rathod PK. Gene organization of a Plasmodium falciparum serine hydroxymethyltransferase and its functional expression in Escherichia coli. Molecular and Biochemical Parasitology 2000; 110:283-291.
87. Ruszkowski M, Sekula B, Ruszkowska A, et al. Structural basis of methotrexate and pemetrexed action on serine hydroxymethyltransferases revealed using plant models. Scientific Reports 2019;9:1-14.
88. Bohnert JA, Szymaniak-Vits M, Schuster S, et al. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. Journal of Antimicrobial Chemotherapy 2011;66:2057-60.
89. Timson J. Hydroxyurea. Mutation Research/Reviews in Genetic Toxicology 1975;32:115-31.
論文の公開元へ
